Francisco Silva - 18 Mar 2022 Form 4 Insider Report for BioRestorative Therapies, Inc. (BRTX)

Role
VP of Research and Development, Director
Signature
/s/ Francisco Silva
Issuer symbol
BRTX
Transactions as of
18 Mar 2022
Net transactions value
$0
Form type
4
Filing time
22 Mar 2022, 17:11:05 UTC
Previous filing
22 Nov 2021
Next filing
08 Jun 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BRTX Common Stock Award +12,438 +8.4% 161,286 18 Mar 2022 Direct F1, F2
holding BRTX Common Stock 11,829 18 Mar 2022 IRA

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding BRTX Stock Option 1 18 Mar 2022 Common Stock 1 $3000.00 Direct F3
holding BRTX Stock Option 1 18 Mar 2022 Common Stock 1 $3000.00 Direct F3
holding BRTX Stock Option 1 18 Mar 2022 Common Stock 1 $3000.00 Direct F3
holding BRTX Stock Option 3 18 Mar 2022 Common Stock 3 $3000.00 Direct F3
holding BRTX Stock Option 1 18 Mar 2022 Common Stock 1 $3000.00 Direct
holding BRTX Stock Option 1 18 Mar 2022 Common Stock 1 $3000.00 Direct
holding BRTX Stock Option 9 18 Mar 2022 Common Stock 9 $3000.00 Direct F3
holding BRTX Stock Option 6 18 Mar 2022 Common Stock 6 $3000.00 Direct F3
holding BRTX Stock Option 15 18 Mar 2022 Common Stock 15 $3000.00 Direct F3
holding BRTX Stock Option 20 18 Mar 2022 Common Stock 20 $3000.00 Direct F3
holding BRTX Stock Option 25 18 Mar 2022 Common Stock 25 $3000.00 Direct F3
holding BRTX Stock Option 293,479 18 Mar 2022 Common Stock 293,479 $13.50 Direct F4
holding BRTX Stock Option 42,059 18 Mar 2022 Common Stock 42,059 $13.50 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares received pursuant to a restricted stock unit grant. Vests in twelve nearly equal monthly installments beginning on April 18, 2022.
F2 Includes 110,264 shares received pursuant to unvested restricted stock unit grants. Such shares vest to the extent of 1,037 shares beginning on April 18, 2022 and continuing monthly through September 18, 2022, 1,036 shares beginning on October 18, 2022 and continuing monthly through February 18, 2023, 49,949 shares on March 18, 2023 and 48,913 shares on March 18, 2024.
F3 The option is currently exercisable.
F4 The option vests and becomes exercisable to the extent of 146,740 shares on March 18, 2021, 36,684 shares on November 4, 2021 and the remaining 110,055 shares in six nearly equal quarterly installments beginning December 18, 2021 and continuing every three months thereafter until fully vested.
F5 The option vests and becomes exercisable to the extent of 21,030 shares on November 4, 2021 with the remaining 21,029 shares vesting quarterly in eight nearly equal installments beginning on November 4, 2022.